Across the recent three months, 9 analysts have shared their insights on Legend Biotech LEGN, expressing a variety of opinions spanning from bullish to bearish.

。

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

下表简要概述了分析师最近的评级，洞察了过去30天不断变化的情绪，并从整体角度与前几个月进行了比较。

Bullish

看涨

Somewhat Bullish

有点看涨

Indifferent

漠不关心

Somewhat Bearish

有点看空

Bearish

看跌

Total Ratings

6

6

3

3

0

0

0

0

0

0

Last 30D

最近30天

1

1

0

0

0

0

0

0

0

0

1M Ago

100万年前

3

3

1

1

0

0

0

0

0

0

2M Ago

200万年前

1

1

0

0

0

0

0

0

0

0

3M Ago

300万年前

1

1

2

2

0

0

0

0

0

0

In the assessment of 12-month price targets, analysts unveil insights for Legend Biotech, presenting an average target of $77.67, a high estimate of $86.00, and a low estimate of $73.00. Marking an increase of 2.36%, the current average surpasses the previous average price target of $75.88.

在对12个月价格目标的评估中，分析师揭示了联想生物技术的见解，平均目标为77.67美元，高估计为86.00美元，低估计为73.00美元。目前的平均价格比之前75.88美元的平均价格目标高出2.36%。

Analyzing Analyst Ratings: A Detailed Breakdown

分析分析师评级：详细细分

The standing of Legend Biotech among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

通过对最近分析师行动的透彻分析，联想生物科技在金融专家中的地位变得清晰起来。下面的摘要概述了主要分析师、他们最近的评估以及对评级和价格目标的调整。

Analyst

分析员

Analyst Firm

分析公司

Action Taken

采取行动

Rating

评级

Current Price Target

当前价格目标

Prior Price Target

先前价格目标

Mitchell Kapoor

米切尔·卡普尔

HC Wainwright & Co.

HC Wainwright&Co。

Maintains

维护

Buy

购买

$73.00

$73.00

$73.00

$73.00

Qize Ding

丁启泽

Redburn Atlantic

Redburn大西洋

Announces

宣布

Buy

购买

$86.00

$86.00

-

-（笑声）

Mitchell Kapoor

米切尔·卡普尔

HC Wainwright & Co.

HC Wainwright&Co。

Maintains

维护

Buy

购买

$73.00

$73.00

$73.00

$73.00

Mitchell Kapoor

米切尔·卡普尔

HC Wainwright & Co.

HC Wainwright&Co。

Maintains

维护

Buy

购买

$73.00

$73.00

$73.00

$73.00

Leonid Timashev

列昂尼德·蒂马舍夫

RBC Capital

加拿大皇家银行

Maintains

维护

Outperform

表现优异

$86.00

$86.00

$86.00

$86.00

Mitchell Kapoor

米切尔·卡普尔

HC Wainwright & Co.

HC Wainwright&Co。

Maintains

维护

Buy

购买

$73.00

$73.00

$73.00

$73.00

Leonid Timashev

列昂尼德·蒂马舍夫

RBC Capital

加拿大皇家银行

Maintains

维护

Outperform

表现优异

$86.00

$86.00

$86.00

$86.00

George Farmer

乔治·法么

Scotiabank

Sctiablank

Raises

提高

Sector Outperform

$76.00

$76.00

$70.00

$70.00

Mitchell Kapoor

米切尔·卡普尔

HC Wainwright & Co.

HC Wainwright&Co。

Maintains

维护

Buy

购买

$73.00

$73.00

$73.00

$73.00

Key Insights:

关键见解：

Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Legend Biotech. This information offers a snapshot of how analysts perceive the current state of the company..

采取的行动：分析师应对市场状况和公司业绩的变化，经常更新他们的建议。无论他们是“维持”、“提高”还是“降低”自己的立场，这都反映了他们对联想生物科技（Legend Biotech）近期发展的反应。这些信息提供了分析师如何看待公司现状的快照。。

Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Legend Biotech compared to the broader market.

评级：分析师揭示了对股票的定性评估，从“表现优异”到“表现不佳”。这些评级提供了对联想生物技术相对于更广泛市场相对表现的预期的见解。

Price Targets: Understanding forecasts, analysts offer estimates for Legend Biotech's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

价格目标：了解预测，分析师提供联想生物科技未来价值的估计。检查当前和之前的目标可以洞察分析师不断变化的预期。

For valuable insights into Legend Biotech's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

要深入了解联想生物科技的市场表现，请将这些分析师评估与关键财务指标一起考虑。保持消息灵通，并使用我们的评级表做出谨慎的决定。

Stay up to date on Legend Biotech analyst ratings.

了解Legend Biotech分析师的最新评级。

Discovering Legend Biotech: A Closer Look

探索传奇生物技术：近距离观察

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma.

Legend Biotech Corp是一家临床阶段的生物制药公司。它致力于发现和开发用于肿瘤学和其他适应症的新型细胞疗法。该公司的主要候选产品LCAR-B38M/JNJ-4528是一种用于治疗多发性骨髓瘤的嵌合抗原受体或CAR T细胞疗法。

Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue..

就地理位置而言，该公司的大部分收入来自美国。该公司从许可和协作收入中产生收入。。

Legend Biotech: A Financial Overview

联想生物科技：财务概述

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

市值：与行业平均水平相比，该公司的规模有所缩小，这表明该公司的市值构成了独特的挑战。

Positive Revenue Trend: Examining Legend Biotech's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 154.36% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector..

积极的收入趋势：检查Legend Biotech超过3个月的财务状况，可以发现积极的叙述。截至2024年6月30日，该公司实现了154.36%的收入增长率，显示了收入的大幅增长。与竞争对手相比，该公司的增长率超过了预期，高于医疗保健行业同行的平均水平。。

Net Margin: Legend Biotech's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -9.76%, the company showcases strong profitability and effective cost management.

净利润率：联想生物科技的财务实力体现在其异常的净利润率上，这超过了行业平均水平。该公司净利润率为-9.76%，表现出强大的盈利能力和有效的成本管理。

Return on Equity (ROE): Legend Biotech's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.57%, the company may face hurdles in achieving optimal financial performance.

股本回报率（ROE）：联想生物科技的ROE落后于行业平均水平，这表明在最大化股本回报方面存在挑战。由于ROE为-1.57%，该公司在实现最佳财务业绩方面可能面临障碍。

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.02%, the company may need to address challenges in generating satisfactory returns from its assets.

资产回报率（ROA）：该公司的ROA低于行业基准，表明有效利用资产存在潜在困难。由于ROA为-1.02%，该公司可能需要解决从其资产中产生令人满意的回报的挑战。

Debt Management: With a below-average debt-to-equity ratio of 0.29, Legend Biotech adopts a prudent financial strategy, indicating a balanced approach to debt management.

债务管理：Legend Biotech的债务股本比低于平均水平0.29，因此采取了谨慎的财务战略，表明债务管理采取了平衡的方法。

What Are Analyst Ratings?

什么是分析师评级？

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Benzinga追踪了150家分析公司，并报告了他们的股票预期。分析师通常通过预测一家公司未来（通常是未来五年）将赚多少钱，以及该公司收入流的风险或可预测性来得出结论。

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

分析师参加公司电话会议，研究公司财务报表，并与内部人士沟通，公布他们对股票的评级。分析师通常每季度或公司有重大更新时对每只股票进行一次评级。

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

分析师可能会通过对增长预期、收益和收入等指标的预测来补充评级，为投资者提供更全面的前景。然而，投资者应该注意，分析师和任何人一样，可能会有主观的观点影响他们的预测。

Breaking: Wall Street's Next Big Mover

突破：华尔街的下一个大推动者

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

Benzinga的#1分析师刚刚确定了一只即将爆发式增长的股票。随着主要市场变化的展开，这家在雷达监视下的公司可能会激增200%。单击此处了解紧急详细信息。

This article was generated by Benzinga's automated content engine and reviewed by an editor.Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

本文由Benzinga的自动内容引擎生成，并由编辑审阅。Benzinga API为您带来的市场新闻和数据©2024 Benzinga.com。Benzinga不提供投资建议。保留所有权利。